Danaher Corporation (DHR)
Danaher Q3 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR Q3 earnings and sales beat estimates, driven by solid segment growth and stronger operating margins.
Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR ) Q3 2025 Earnings Call October 21, 2025 8:00 AM EDT Company Participants John Bedford - Vice President of Investor Relations Rainer Blair - President, CEO & Director Matt McGrew - CFO & Executive VP Conference Call Participants Michael Ryskin - BofA Securities, Research Division Tycho Peterson - Jefferies LLC, Research Division Scott Davis - Melius Research LLC Douglas Schenkel - Wolfe Research, LLC Vijay Kumar - Evercore ISI Institutional Equities, Research Division Daniel Brennan - TD Cowen, Research Division Jack Meehan - Nephron Research LLC Puneet Souda - Leerink Partners LLC, Research Division Presentation Operator My name is David, and I'll be your conference facilitator this morning. At this time, I'd like to welcome everyone to Danaher Corporation's Third Quarter 2025 Earnings Results Conference Call.
Danaher beats quarterly estimates on strength in diagnostic tools and tech
Life Sciences firm Danaher on Tuesday beat Wall Street's third-quarter profit and revenue estimates, buoyed by resilient demand for its diagnostic testing tools and services, sending its shares up 1.3% in premarket trading.
LH vs. DHR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
DHR gears up for Q3 results with steady earnings estimates and mixed segment trends across Life Sciences, Biotechnology and Diagnostics.
Danaher: Balanced Portfolio With Upside Potential In 2026
Danaher is undervalued, with strong fundamentals, robust free cash flow, and a "Buy" rating targeting $210 (12.7% upside). DHR's bioprocessing segment drives growth, balancing Life Sciences weakness, while 80% recurring revenue ensures stable cash flows. Management raised adjusted EPS guidance for 2025, citing cost efficiency and sustained bioprocessing demand; further margin recovery could boost optimism.
Danaher (DHR) Up 6.8% Since Last Earnings Report: Can It Continue?
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Danaher (DHR) Just Overtook the 200-Day Moving Average
Danaher (DHR) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, DHR broke through the 200-day moving average, which suggests a long-term bullish trend.
CVS or DHR: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
International Markets and Danaher (DHR): A Deep Dive for Investors
Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Investors decided the good outweighs the bad with Danaher, says Jim Cramer
'Mad Money' host Jim Cramer talks how to play Danaher after earnings.
Danaher Q2 2025 Update
While the worst seem to be behind them, the business isn't quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year adjusted diluted net EPS guidance to a range of $7.70 to $7.80 vs previous range of $7.60 to $7.75. Compared to the past few years, Danaher's multiples have noticeably come down. However, it is hard for a stock to go up if revenue growth hovers around LSD level.
